Open Access Open Access  Restricted Access Subscription or Fee Access

Edifice of Remedy Network Plinth on Side Effects with Allege for Remedy Deputy

C. Bala Saravanan

Abstract


Remedies with similar side-effect silhouette may share comparable beneficial assets from beginning to end interrelated apparatus of deed. In this study, a remedy-remedy intricate was erect pedestal on the resemblance amid their clinical side effects. The hint of a remedy may be unreliable by the enriched FDA matured congregation of its adjoining remedies in the alliance. We haphazardly panel imaginative allusion for 1745 remedies with supplementary than two complex neighbors, 59.98% of the remedies bring about a piece accomplish of normalize bargain crypt priced swelling which revenue the prime part of the known FDA-official clue were well envisage at the top 5 positions. In particular, remedies for diabetes, stoutness, laxatives and antimycobacterials had awfully tall concert with more than 97% of them achieving besides, by corporal checking the predicted 1808 remedy-warning pairs with Idiom Scrutiny Efficient Voyager (ISEV) we found that 90.73% of such pairs could be inveterate by preclinical/clinical cram or precise dedication. Besides, our comportment could be extended to envisage remedies not covered in the network. Remedies with noteworthy likeness to other remedies in the establish of acquaintances.

Keywords


TOB, FDA, COMT, QSAR, ISEV.

Full Text:

PDF

References


Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al. (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Remedy Discov 9: 203–214.

David E, Tramontin T, Zemmel R (2009) Pharmaceutical R&D: the road to positive returns. Nat Rev Remedy Discov 8: 609–610.

Berggren R, Moller M, Moss R, Poda P, Smietana K (2012) Outlook for the next 5 years in remedy innovation. Nat Rev Remedy Discov 11: 435–436.

Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Remedy Discov 3: 711–715.

Ashburn TT, Thor KB (2004) Remedy repositioning: identifying and developing new uses for existing remedies. Nat Rev Remedy Discov 3: 673–683.

Wu Z, Wang Y, Chen L (2013) Network-based remedy repositioning. Mol Biosyst 9: 1268–1281.

Opera TI, Mestres J (2012) Remedy repurposing: far beyond new targets for old remedies. AAPS J 14: 759–763.

Liu X, Zhu F, Ma XH, Shi Z, Yang SY, et al. (2013) Predicting targeted polypharmacology for remedy repositioning and multi- target remedy discovery. Curr Med Chem 20: 1646–1661.

Lamb J, Crawford ED, Peck D, Modell JW, and Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929–1935.

Lou H, Chen J, Shi L, Mikailov M, Zhu H, et al. (2011) DRAR-CPI: a server for identifying remedy repositioning potential and adverse remedy reactions via the Chemical-protein interactive. Nucleic Acids Res 39: W492–498.

Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, et al. (2012) Predicting new indications for approved remedies using a proteochemometric method. J Med Chem. 55: 6832–6848.

Cheng F, Zhou Y, Li J, Li W, Liu G, et al. (2012) Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemo genomic methods.Mol Biosyst 8: 2373–2384.

Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, et al. (2012) Use of genome-wide association studies for remedy repositioning. Nat Biotechnology 30: 317–320.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.